NanoRepro AG: management transactions · Germany · BaFin

About NanoRepro AG

NanoRepro AG is a German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) and headquartered in Marburg, Hesse, Germany. Since its stock market listing in October 2008, the group has focused on the development, manufacturing and distribution of rapid diagnostic self-tests for home and professional use, together with food supplements. Its core positioning is in preventive healthcare and self-diagnostics, a market supported by rising health awareness, consumer demand for convenient at-home testing, and multi-channel distribution across pharmacy, retail and online channels. ([nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai)) From a business-model perspective, NanoRepro built its franchise around the “ZuhauseTEST” brand and a CE-marked portfolio covering areas such as fertility, pregnancy, gastric health, intolerances, allergies, preventive screening and infectious diseases. The company emphasizes product flexibility, just-in-time manufacturing and ongoing cost optimization, which are important advantages for a niche diagnostics player operating in a fast-moving consumer-health environment. Alongside diagnostics, NanoRepro has offered food supplements under the ALPHABIOL brand since 2015, allowing it to cross-sell within adjacent health and wellness categories. ([nanorepro.com](https://www.nanorepro.com/unternehmen?utm_source=openai)) In competitive terms, NanoRepro is best viewed as a focused small-cap specialist rather than a fully integrated large healthcare group. Its edge lies in speed, targeted product launches, and the combination of diagnostics with consumer health products. The company serves both domestic and international markets, although Germany remains the anchor market and operational base. Recent disclosures also indicate growing retail presence, including listings with major German drugstore partners, which supports broader brand visibility and distribution reach. ([nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai)) Recent developments are especially relevant for investors. After the COVID-test windfall faded, NanoRepro reported a clear recovery in its underlying business in 2024, with core revenue outside COVID rising by roughly 76% and total revenue reaching about EUR 4.4 million. Subsequent half-year and full-year updates for 2024/2025 show continued momentum in self-tests and supplements, while profitability is still in transition. At the same time, the company has broadened its strategic optionality through a majority stake in Paedi Protect AG and a 2025 investment in hyped about science GmbH, linked to cold-plasma technology and the PHLAS consumer device. For international equity investors, NanoRepro combines healthcare exposure, balance-sheet-driven caution, and a diversification strategy that is still being built out. ([nanorepro.com](https://www.nanorepro.com/presse-news/pressemitteilungen-de/nanorepro-veroeffentlicht-halbjahreszahlen-2024-umsatz-im-kerngeschaeft-steigt-investitionen-in-markenbekanntheit-zahlen-sich-aus?utm_source=openai))